Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26009600 | 0.82 | ATR (0.58) | ATR | |
| SCHEMBL27050959 | 0.82 | ATR (0.67) | ATR | |
| SCHEMBL17501293 | 0.81 | ATR (1.00) | ATR | |
| SCHEMBL20081975 | 0.81 | ATR (1.00) | ATR | |
| SCHEMBL18109994 | 0.80 | ATR (0.72) | ATR | |
| SCHEMBL18109995 | 0.80 | ATR (0.72) | ATR | |
| SCHEMBL23837712 | 0.79 | ATR (1.00) | ATR | |
| SCHEMBL17501026 | 0.79 | ATR (1.00) | ATR | |
| SCHEMBL20081897 | 0.79 | ATR (1.00) | ATR | |
| SCHEMBL27050848 | 0.79 | ATR (0.53) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4230628-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ATR, ATRIP, CHEK2 | ATR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.